Home | Community | Message Board


This site includes paid links. Please support our sponsors.


Welcome to the Shroomery Message Board! You are experiencing a small sample of what the site has to offer. Please login or register to post messages and view our exclusive members-only content. You'll gain access to additional forums, file attachments, board customizations, encrypted private messages, and much more!

Shop: Myyco.com Golden Teacher Liquid Culture For Sale   OlympusMyco.com Olympus Myco Bulk Substrate   Original Sensible Seeds Autoflowering Cannabis Seeds   Mushroom-Hut Mono Tub Substrate   North Spore North Spore Mushroom Grow Kits & Cultivation Supplies   Kraken Kratom Kratom Capsules for Sale   MagicBag.co All-In-One Bags That Don't Suck   Left Coast Kratom Buy Kratom Extract

Jump to first unread post Pages: 1
InvisibleMycodemus
wrong way down a one way street
I'm a teapot User Gallery


Registered: 01/27/23
Posts: 436
Swedish nonprofit Norrsken Mind to initiate research into psychedelics for mental health * 1
    #28482464 - 09/25/23 02:45 PM (7 months, 19 days ago)

https://www.norrskenmind.org/news-updates/norrsken-mind-raises-36-msek-to-support-research-on-psychedelic-substances

Sweden is well behind the curve on this (as well as being stuck in reefer madness ideology in general on drugs), so it’s nice to see initiatives taken in the startup/nonprofit sector. Hopefully a ripple which will help create a sea change. 36 million SEK is about $3,255,000 or €3,073,000.


Norrsken Mind raises 36 MSEK to support psychedelic science
September 13, 2023



Today marks the launch of Norrsken Mind: Psychedelic Science Initiative, a Swedish foundation focused on supporting research on psychedelic substances and their potential to treat mental health disorders. A total of SEK 36 million has been committed by Norrsken Foundation (30 MSEK), Huxley Foundation (3 MSEK) and Nordlander Zeidler Family Foundation (3 MSEK). Norrsken Mind will fund a study at Karolinska Institutet to investigate the cognitive and neurobiological changes associated with psilocybin-assisted therapy, which may offer insights into the neurobiology of major depressive disorder and the therapeutic mechanisms of psilocybin. Norrsken Mind has also granted partial funding to a study under planning at Umeå University to investigate MDMA-assisted psychotherapy as a treatment for depression in young adults (aged 18-25).

Public agencies and authorities across the world, such as the European Medicines Agency1, are increasingly recognizing that psychedelic-assisted therapies look promising to tackle several mental health conditions. Despite extensive international research, Sweden is far behind on both psychedelic research and treatment competence.

Norrsken Mind is a new foundation that will support research to further investigate the potential of psychedelic-assisted treatments and enable Sweden to catch up in this area of research.

“Research on psychedelic-assisted treatments is one of the most promising lines of research in the field of psychiatry right now. While there are several important mental health treatments today, they are in many cases insufficient, and we need to explore new ways forward. There are plenty of interested researchers in Sweden and across Europe, and with the right funding and conditions in place, we can help them investigate more effective treatment options, accelerate psychedelic research, and ensure that Sweden does not stay behind the rest of the world,” says Emma Christersson, Managing Director of Norrsken Mind.

“The most important factor in developing more effective mental health treatments is high-quality research, and that requires substantial capital. Through this initiative, we aim to generate more funding to catalyse more much-needed research in this area. Norrsken has previously made donations to fund research on psilocybin-assisted therapy for depression and invested in the psychedelic field. Over the past few years, our conviction of the importance of investing in mental health has only increased. There is a growing body of evidence suggesting that psychedelic-assisted treatments can be used to treat a variety of mental health disorders,” says Funda Sezgi, Co-CEO of Norrsken Foundation.

The launch of Norrsken Mind makes more than SEK 30 million available to support research and other projects in this field, with an ambition to raise more funds over the coming years. Norrsken Mind will support researchers in further investigating the treatment potential of psychedelics through fundraising, grant opportunities and by facilitating international collaborations. We will also engage with healthcare professional sand mental health stakeholders to provide information and education on psychedelic research, and intend to support efforts to create better conditions for conducting research.

Norrsken Mind will initially focus on funding research in Sweden and in the near-term broaden its scope to cover research in other European countries as well. Norrsken Mind is today announcing two grants amounting to approximately SEK 7 million to two studies:

●  At Karolinska Institutet, a research team led by Predrag Petrovic, Associate Professor at the Department of Clinical Neuroscience at Karolinska Institutet, will investigate the cognitive and neurobiological changes associated with psilocybin-assisted therapy, which may offer insights into the neurobiology of major depressive disorder and the therapeutic mechanisms of psilocybin. The study will analyze data gathered from PSIPET, a study that investigated psilocybin-assisted psychotherapy for depression at Karolinska Institutet.

●  Norrsken Mind has granted partial funding to a study under planning at Umeå University to investigate MDMA-assisted psychotherapy as a treatment for depression in young adults (aged 18-25). Eva Henje, Associate Professor at Umeå University’s Department of Clinical Science, Child- and Adolescent Psychiatry, will lead the study. The study could become the first of its kind in Sweden to investigate MDMA-assisted psychotherapy.

There has been limited progress in developing more effective treatments over the past decades. During that time, the costs resulting from mental health conditions have continued to increase and estimates indicate that the annual global costs could amount to USD 6 trillion by 20302. There is little to indicate that this trend will be halted in the near term.

Promising results emerging from psychedelic research over the past few years have led many to feel hopeful. However, more research is needed to determine the potential risks and effectiveness of psychedelic-assisted treatments. Given the global urgency of the issue of mental health, it is paramount to further investigate psychedelics and establish if and how they can be used as treatments.


About Norrsken Mind

Norrsken Mind is a foundation focused on supporting research on psychedelic substances and their potential to treat mental health disorders through fundraising and grant opportunities. Our goal is to catalyse more research in Sweden and across Europe to improve the understanding of psychedelic-assisted treatments, as well as to inform and engage with mental health stakeholders through education and training efforts. Norrsken Mind is a continuation of Osmond Foundation, which funded the first Swedish modern clinical trial using psilocybin-assisted therapy to treat depression at Karolinska Institutet.

About Norrsken

Norrsken is an impact ecosystem where entrepreneurs can find everything they need to make saving the world their business. Our work stems from a belief in entrepreneurship and new technology as forces that can positively impact the world.

We run award-winning Norrsken House hubs in Stockholm, Sweden, Kigali, Rwanda and (soon) Barcelona, Spain. Norrsken’s five funds have raised >500m USD to back exceptional entrepreneurs who combine profit with positive global impact: Norrsken VC, Norrsken22, Norrsken Accelerator, Norrsken Launcher and Norrsken Africa Seed Fund.

Norrsken is a non-profit, non-partisan and non-religious foundation. It was founded by Niklas Adalberth, co-founder of payment services unicorn Klarna.

References

1. Steffen Thirstrup, Chief Medical Officer at European Medicines Agency (2023). A second chance to psychedelics. Linkedin. https://www.linkedin.com/pulse/second-chance-psychedelics-european-medicines-agency/

2. The Lancet Global Health. Mental health matters. Lancet Glob Health. 2020 Nov;8(11):e1352. doi:10.1016/S2214-109X(20)30432-0. PMID: 33069297; PMCID: PMC7561290.


--------------------


An hour and a half later, I was beginning to feel definite effects

Edited by Mycodemus (09/25/23 02:59 PM)

Extras: Filter Print Post Top
InvisibleMycodemus
wrong way down a one way street
I'm a teapot User Gallery


Registered: 01/27/23
Posts: 436
Re: Swedish nonprofit Norrsken Mind to initiate research into psychedelics for mental health [Re: Mycodemus] * 1
    #28482534 - 09/25/23 03:24 PM (7 months, 19 days ago)

https://www.bloomberg.com/news/newsletters/2023-09-15/swedish-mdma-lab-hopes-to-ease-mental-health-crisis?embedded-checkout=true#xj4y7vzkg


Getting high to ease depression
Norrsken House might sound like a genre of club music, but it’s an office space in Stockholm devoted entirely to people with clever ideas. Emma Christersson is one such bright spark.

Christersson heads up Norrsken Mind, a newly-formed Swedish foundation that hopes to foster a wave of research into the chemical compounds found in “magic mushrooms” and the party drug “ecstasy” and their potential to treat mental health disorders.

A graduate of cognitive neuroscience, Christersson calls mental illness “one of the defining issues of our time.” Some 1 billion people around the world suffer from mental disorders, according to the World Health Organization, while the Covid-19 pandemic led to rates of depression more than doubling among young people, findings by the European Commission reveal.

One of the first projects to be awarded a grant by Norrsken Mind will be a study under planning at Umeå University to investigate MDMA-assisted psychotherapy as a treatment for depression in people aged 18 to 25.

“If approved this will be the first clinical study in the world to focus on depression for young adults,” she says.

MDMA is an amphetamine derivative that’s the active ingredient in the club drug ecstasy. Exceptional results have been found with MDMA in a trial with war veterans, sexual assault survivors and other sufferers from severe post-traumatic stress disorder (PTSD), a notoriously treatment-resistant condition. The US Food and Drug Administration has issued breakthrough therapy status to MDMA, as well.

So what goes on in these trials? Typically a patient will do a lot of preparatory work with specially trained therapists so a level of trust is built up. Then, over one to three sessions in a safe clinical setting the patient will take a dose of drugs such as psilocybin, DMT or mescaline (which activate serotonin receptors in the brain) or other compounds such as MDMA (a major releaser of serotonin).

During the so-called trip the patient can undergo a profound inner exploration of one’s perception of self and, combined with follow-up therapy, those experiences can lead to a lasting reduction of suffering.

“This is a completely new form of therapy,” says Christersson, adding that treatments conducted elsewhere have shown “really promising results.”

The US experience with psychedelics offers a blueprint for how it can be done in Sweden, which is behind other countries, according to Christersson, as it has had only had one clinical trial at the Karolinska Institute for psilocybin-assisted therapy.

MDMA is one of most studied substances in the US, in particular its use to potentially treat PTSD by the non-profit Multidisciplinary Association for Psychedelic Studies, says Christersson. “That shows something can be conducted in a safe clinical setting.” — Charles Daly


--------------------


An hour and a half later, I was beginning to feel definite effects

Extras: Filter Print Post Top
Jump to top Pages: 1

Shop: Myyco.com Golden Teacher Liquid Culture For Sale   OlympusMyco.com Olympus Myco Bulk Substrate   Original Sensible Seeds Autoflowering Cannabis Seeds   Mushroom-Hut Mono Tub Substrate   North Spore North Spore Mushroom Grow Kits & Cultivation Supplies   Kraken Kratom Kratom Capsules for Sale   MagicBag.co All-In-One Bags That Don't Suck   Left Coast Kratom Buy Kratom Extract


Similar ThreadsPosterViewsRepliesLast post
* Scientists Say Marijuana Research Blocked Redo 1,216 1 07/21/04 03:32 PM
by Redo
* Mushroom Growers and Researchers Use Coal and Quarry Waste baraka 1,199 1 05/28/04 10:01 AM
by Lana
* Major Research Chem Suppliers Arrested Ravus 2,391 7 08/19/04 12:08 AM
by Randolph_Carter
* On sale: 'mind-blowing' mushrooms motamanM 3,818 3 07/01/03 11:32 AM
by Anonymous
* Research on Ecstasy Is Clouded by Errors cybrbeast 2,348 3 12/16/03 04:36 AM
by zeta
* Alaska Ponders Pot Initiative luvdemshrooms 1,155 3 11/15/05 12:38 PM
by Microcosmatrix
* Initiative to legalize pot fails big veggieM 1,797 0 11/03/04 04:33 AM
by veggie
* American research therapeutic value of XTC stefan 2,436 5 11/28/03 09:58 AM
by DailyPot

Extra information
You cannot start new topics / You cannot reply to topics
HTML is disabled / BBCode is enabled
Moderator: motaman, veggie, Alan Rockefeller, Mostly_Harmless
1,209 topic views. 0 members, 5 guests and 6 web crawlers are browsing this forum.
[ Show Images Only | Sort by Score | Print Topic ]
Search this thread:

Copyright 1997-2024 Mind Media. Some rights reserved.

Generated in 0.022 seconds spending 0.007 seconds on 12 queries.